13-PUB: Semaglutide Reduces Risk of Adverse Limb Events among Patients with Diabetes and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis

Introduction and Objective: The prevalence of peripheral arterial disease (PAD) among individuals with diabetes mellitus is two to seven-fold higher than those without DM. Individually, DM and PAD are contributors to high atherosclerotic cardiovascular disease (ASCVD) risk. Put together, they amplify the risk of mortality and mortality due to ASCVD. We conducted a systematic review and meta-analysis to assess the efficacy of Semaglutide in this population. Methods: Databases (PubMed, EMBASE, Cochrane Central, Scopus) were systematically searched for relevant studies after registration (CRD420251182802). Both randomized and non-randomized studies were included. Binary outcomes were reported as relative risk (RR) for binary outcomes, with 95% confidence intervals and I² statistic for heterogeneity. Results: A total of 4 studies (2 RCTs, 1 post-hoc analysis of an RCT, 1 propensity score matched observational study) with 10,776 patients were included. Gangrene was the most frequently reported limb adverse event in both groups (p=0.219). Semaglutide was associated with a significantly lower risk of major adverse limb events (RR 0.76 [95% CI 0.64-0.91], where the outcome was reported as time to event, HR 0.75 [95% CI 0.65-0.86] I2=0%) Conclusion: Semaglutide is associated with a significantly lower risk of adverse limb events in patients with DM and PAD however, additional RCTs are required to further corroborate this evidence Disclosure P. Deshmukh: None. M. Amaanullah: None. S. Agarwal: None. D. Gutta: None. S. Shah: None. S. Joshi: None. V. Deshmukh: None.